3 unchanged sentences
The term "disclosure controls and procedures,"
−Removed: as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the
−Removed: Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
+Added: as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Based on this evaluation our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2021 at the reasonable assurance level.
21 unchanged sentences
We have adopted a code of ethics for directors, officers (including our principal executive officer, principal financial officer and principal accounting officer) and employees, known as the Code of Business Conduct and Ethics.
−Removed: The Code of Business Conduct and Ethics is available on our website at http://www.xencor.com under the Corporate Governance section of our Investor Relations page.
+Added: The Code of Business Conduct and Ethics is available on our website at https://www.xencor.com under the Corporate Governance section of our Investor Relations page.
We will promptly disclose on our website (i) the nature of any amendment to the policy that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals that is required to be disclosed pursuant to SEC rules and regulations, the name of such person who is granted the waiver and the date of the waiver.
52 unchanged sentences
333-191689), originally filed with the SEC on October 11, 2013).
−Removed: Cross-License Agreement, dated December 19, 2012, by and between the Company and MedImmune, LLC (incorporated by reference to Exhibit 10.26 to the Company’s Registration Statement on Form S-1, as amended (File No.
−Removed: 333-191689), originally filed with the SEC on October 11, 2013).
Lease dated January 1, 2015 by and between the Company and BF Monrovia, LLC (incorporated by reference to Exhibit 99.1 to the Company’s Form 8-K filed with the SEC on January 5, 2015).
23 unchanged sentences
First Amendment to the Research and License Agreement, dated November 22, 2019, by and between the Company and Amgen Inc.
−Removed: Amendment to the Cross-License Agreement, dated January 2, 2020, by and between the Company and MedImmune, LLC.
−Removed: Second Amendment to the License Agreement, dated January 8, 2020, by and between the Company and MorphoSys AG.
−Removed: Third Amendment to the License Agreement, dated July 13, 2020, by and between the Company and MorphoSys AG.
−Removed: Fifth Amendment to Lease, dated October 31, 2020, by and between the Company and 111 Lemon Investors LLC.
+Added: (incorporated by reference to Exhibit 10.29 to the Company’s Form 10-K filed with the SEC on February 23, 2021).
+Added: Second Amendment to the License Agreement, dated January 8, 2020, by and between the Company and MorphoSys AG (incorporated by reference to Exhibit 10.31 to the Company’s Form 10-K filed with the SEC on February 23, 2021).
+Added: Third Amendment to the License Agreement, dated July 13, 2020, by and between the Company and MorphoSys AG (incorporated by reference to Exhibit 10.32 to the Company’s Form 10-K filed with the SEC on February 23, 2021).
+Added: Fifth Amendment to Lease, dated October 31, 2020, by and between the Company and 111 Lemon Investors LLC (incorporated by reference to Exhibit 10.33 to the Company’s Form 10-K filed with the SEC on February 23, 2021).
Collaboration and License Agreement, dated December 4, 2020, by and between the Company and Janssen Biotech, Inc.
+Added: (incorporated by reference to Exhibit 10.34 to the Company’s Form 10-K filed with the SEC on February 23, 2021).
+Added: First Amendment to the Collaboration and License Agreement, dated March 10, 2021, by and between the Company and Genentech, Inc.
+Added: Hoffmann-La Roche LTD (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed with the SEC on May 5, 2021).
+Added: Form of Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 10, 2021).
+Added: Second Amendment to the Collaboration and License Agreement, dated June 30, 2021, by and between the Company and Genentech, Inc., and F.
+Added: Hoffmann-La Roche LTD (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed with the SEC on August 4, 2021).
+Added: Agreement of Lease, dated April 30, 2021, by and between the Company and Angelo Gordon Real Estate, Inc.
+Added: (incorporated by reference to Exhibit 10.2 to the Company’s Form 10-Q filed with the SEC on August 4, 2021).
+Added: First Amendment to Lease, dated July 13, 2021, by and between the Company and Angelo Gordon Real Estate, Inc.
+Added: (incorporated by reference to Exhibit 10.3 to the Company’s Form 10-Q filed with the SEC on August 4, 2021).
+Added: Amended and Restated Non-Employee Director Compensation Policy.
+Added: Collaboration and License Agreement, dated October 1, 2021, by and between the Company and Janssen Biotech, Inc.
Consent of Independent Registered Public Accounting Firm (RSM US LLP) .
29 unchanged sentences
/s/ B ASSIL I.
−Removed: D AHIYAT , PH.D.
+Added: D AHIYAT , P h .D.
Director, President & Chief Executive Officer (Principal Executive Officer)
12 unchanged sentences
/s/ K EVIN C.
−Removed: G ORMAN , PH.D.
+Added: G ORMAN , P h .D.
February 24, 2022
10 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.